MRK
NYSE · Pharmaceuticals
Merck & Co. Inc.
$123.82
+1.56 (+1.28%)
MRK News15 articles
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
Merck Shares Surge to 52-Week High on Deutsche Bank Upgrade
Merck shares climbed to a 52-week high following an upgrade from Deutsche Bank, which raised its price target to $150. The company is set to present new bladder and kidney cancer data later this month.
Moderna Shares Rise on Q4 Beat, Flu Vaccine Faces FDA Hurdle
Moderna shares advanced roughly 5% late Friday after reporting better-than-expected Q4 revenue. The company reaffirmed its 2026 growth targets despite an FDA setback for its seasonal flu vaccine.
Merck Shares Gain on Deutsche Bank Upgrade Ahead of Key Cancer Data
Merck shares advanced following a Deutsche Bank upgrade to Buy and a raised price target, with investors focused on upcoming oncology data at the ASCO GU symposium.
Merck Shares Dip Following Insider Transactions Amid Revenue Forecast Concerns
Merck shares declined 0.5% after SEC filings revealed stock sales by two executives, adding pressure following a revenue outlook that fell short of analyst expectations.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.
Merck Shares Drop on Insider Sale, Investors Await Key FDA Decision
Merck & Co. stock fell 3.5% amid an executive share sale and underperformance versus a broader market rally. Traders are focused on an upcoming FDA ruling for Keytruda's ovarian cancer expansion.
Dow Holds 50,000 as Markets Await Key Jobs, Inflation Data
The Dow Jones Industrial Average edged up 17 points to 50,132.79, maintaining its position above the 50,000 threshold. Investors are focused on upcoming employment and inflation reports, which could influence Federal Reserve policy.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
Dow Retreats from 50K Milestone as Investors Await Inflation, Jobs Data
The Dow Jones Industrial Average edged lower Monday after its historic close above 50,000, while the S&P 500 and Nasdaq gained on tech strength. Markets are focused on upcoming inflation and employment reports.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Dow Retreats Below 50,000 as Rotation Hits Tech; Key Economic Data Awaited
The Dow Jones Industrial Average fell below the 50,000 mark in Monday trading, pressured by a shift out of technology stocks. Investors await critical payrolls and inflation reports later this week.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
Merck Shares Approach 52-Week High on Canadian RSV Drug Approval
Merck stock gained 1.8% after Health Canada approved its ENFLONSIA RSV antibody for infants. Guggenheim raised its price target to $140, while insider sales were disclosed.